Eli Lilly and Stock Forecast, Price & News

Eli Lilly and's stock was trading at $140.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, LLY shares have increased by 49.3% and is now trading at $209.09.
View which stocks have been most impacted by COVID-19.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last year. There are currently 4 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Eli Lilly and stock.
View analyst ratings for Eli Lilly and or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Eli Lilly and a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eli Lilly and wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

399 employees have rated Eli Lilly and CEO David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among Eli Lilly and's employees.

Eli Lilly and is scheduled to release its next quarterly earnings announcement on Friday, January 29th 2021.
View our earnings forecast for Eli Lilly and.

Eli Lilly and will be holding an earnings conference call on Friday, January 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Eli Lilly and Company (NYSE:LLY) posted its earnings results on Sunday, November, 1st. The company reported $1.54 earnings per share for the quarter, missing the Zacks' consensus estimate of $1.71 by $0.17. The company had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.87 billion. Eli Lilly and had a net margin of 24.01% and a trailing twelve-month return on equity of 166.45%. Eli Lilly and's quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the company posted $1.48 earnings per share.
View Eli Lilly and's earnings history.

Eli Lilly and declared a quarterly dividend on Monday, December 14th. Stockholders of record on Friday, February 12th will be paid a dividend of $0.85 per share on Wednesday, March 10th. This represents a $3.40 annualized dividend and a dividend yield of 1.63%. The ex-dividend date of this dividend is Thursday, February 11th. This is a positive change from Eli Lilly and's previous quarterly dividend of $0.74.
View Eli Lilly and's dividend history.

Eli Lilly and pays an annual dividend of $2.96 per share and currently has a dividend yield of 1.44%. Eli Lilly and does not yet have a strock track record of dividend growth. The dividend payout ratio of Eli Lilly and is 49.01%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 37.09% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.
View Eli Lilly and's dividend history.

Eli Lilly and issued an update on its FY21 earnings guidance on Tuesday, December, 15th. The company provided earnings per share (EPS) guidance of $7.75-8.40 for the period, compared to the Thomson Reuters consensus estimate of $8.00. The company issued revenue guidance of $26.5-28.0 billion, compared to the consensus revenue estimate of $26.39 billion.

15 brokers have issued 1 year price targets for Eli Lilly and's stock. Their forecasts range from $144.00 to $225.00. On average, they expect Eli Lilly and's share price to reach $179.57 in the next twelve months. This suggests that the stock has a possible downside of 14.1%.
View analysts' price targets for Eli Lilly and or view Wall Street analyst' top-rated stocks.

Eli Lilly and saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 6,890,000 shares, an increase of 24.1% from the December 15th total of 5,550,000 shares. Based on an average daily volume of 4,150,000 shares, the days-to-cover ratio is presently 1.7 days. Approximately 0.9% of the shares of the company are short sold.
View Eli Lilly and's Short Interest.

Some companies that are related to Eli Lilly and include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Endo International (ENDP) and Supernus Pharmaceuticals (SUPN).
View all of LLY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), The Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Eli Lilly and's stock is owned by many different retail and institutional investors. Top institutional investors include OLD National Bancorp IN (0.07%), Atalanta Sosnoff Capital LLC (0.04%), Private Capital Advisors Inc. (0.04%), State of Alaska Department of Revenue (0.03%), Gateway Investment Advisers LLC (0.03%) and DNB Asset Management AS (0.03%). Company insiders that own Eli Lilly and stock include Aarti S Shah, Alfonso G Zulueta, Anne E White, Christi Shaw, David A Ricks, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill and Stephen F Fry.
View institutional ownership trends for Eli Lilly and.

LLY stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Gateway Investment Advisers LLC, Candriam Luxembourg S.C.A., Avantax Advisory Services Inc., Atalanta Sosnoff Capital LLC, KG&L Capital Management LLC, Fulton Breakefield Broenniman LLC, and State of Alaska Department of Revenue. Company insiders that have sold Eli Lilly and company stock in the last year include Aarti S Shah, Alfonso G Zulueta, Lilly Endowment Inc, Melissa S Barnes, Myles O'neill, and Stephen F Fry.
View insider buying and selling activity for Eli Lilly and or view top insider-selling stocks.

LLY stock was acquired by a variety of institutional investors in the last quarter, including Cadinha & Co. LLC, Crossmark Global Holdings Inc., Private Capital Advisors Inc., Sarasin & Partners LLP, Kestra Advisory Services LLC, Journey Advisory Group LLC, Crescent Capital Consulting LLC, and Rhenman & Partners Asset Management AB. Company insiders that have bought Eli Lilly and stock in the last two years include Anne E White, David A Ricks, Jackson P Tai, and Joshua L Smiley.
View insider buying and selling activity for Eli Lilly and or or view top insider-buying stocks.

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LLY stock can currently be purchased for approximately $209.09.

Eli Lilly and has a market capitalization of $200.01 billion and generates $22.32 billion in revenue each year. The company earns $8.32 billion in net income (profit) each year or $6.04 on an earnings per share basis. Eli Lilly and employs 33,625 workers across the globe.

The official website for Eli Lilly and is www.lilly.com.

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]